(Q33348291)

English

A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

prostate carcinoma

1 reference

based on heuristic

inferred from title

author name string

Lance C Pagliaro

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ebrahim S Delpassand

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dallas Williams

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Randall E Millikan

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shi-Ming Tu

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christopher J Logothetis

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

97

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2988-2994

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Radioisotopes in the treatment of bone metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly doxorubicin in endocrine-refractory carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11412

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11412

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33348291&oldid=1536721009"